Hospital Cuf Descobertas S.A. — Clinical Trial Site

76 Registered trials

28 Currently recruiting

Organisation

Hospital Cuf Descobertas S.A.

Location

Lisbon, Portugal

Identifier

ORG-100041451

Address

Rua Mario Botas 1, 1998-018, Portugal

Departments

-
#2104: Servico Imunoalergologia
2704; Serviço de Dermatologia
3302: Serviço de Dermatologia
351002: Oncologia Medica
5002:Serviço de Hemato-Oncologia
9230: Serviço de Dermatologia
Allergology
Cardiologia
Cardiology Department
Centro de Alergia
Centro de Dermatologia
Dermatologia
Dermatology
Dermatology Department
Hemato-Oncologia
Medical Oncology
N/A
na
Neurology
Oftalmologia
Oncologia
Oncology
Oncology Department
Paediatrics
Pediatria
Pulmonology department
Rheumatology
Serviço de Dermatologia
Serviço de Hemato-oncologia
Serviço de Nefrologia
Serviço de Oncologia
Serviço de Oncologia Médica
Serviço de Pediatria

Clinical trials at this site (76)

Search interface

Phase 3 Study Assessing Rocatinlimab (AMG 451) in Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Orbit) Not authorised

2022-501535-16-00 Atopic Dermatitis (AD) 5
A Phase 3 extension study to assess the long-term safety and efficacy of remibrutinib in adult participants with moderate to severe hidraden… Pending

2025-523259-72-00 Hidradenitis Suppurativa (HS) 5
PODOMOUNT-Basket, a study to test whether BI 764198 helps adults and adolescents with different types of kidney disease Pending

2025-523425-17-00 Proteinuric kidney diseases 4
Randomised, Multicentre, Multinational, Double-Blind Integrated Study to Compare the Pharmacokinetics, Efficacy, Safety, and Immunogenicity … Recruiting

2025-521562-95-00 Previously Untreated Advanced (Unresectable or Metastat 5 2025-12-30
Phase III clinical trial to evaluate the efficacy and safety of specific immunotherapy with mannanconjugated allergoids for the treatment of… Recruiting

2023-508547-51-00 Aetiological treatment of moderate-to-severe allergic r 5 2025-11-18
A PHASE 2 STUDY TO RESEARCH THE SAFETY AND EFFICACY OF TRASTUZUMAB DERUXTECAN VERSUS CDK4/6I PLUS ENDOCRINE THERAPY IN ADVANCED BREAST CANCE… Recruiting

2024-512360-55-00 Unresectable locally recurrent or metastatic hormone re 4 2025-06-30
An Extension Study to Evaluate Safety, Efficacy, and Durability of Response to ESK-001 for Moderate to Severe Plaque Psoriasis (ONWARD3) Recruiting

2024-511166-36-00 Moderate to Severe Plaque Psoriasis 5 2025-06-13
A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Pso… Recruiting

2024-515706-77-00 Moderate to Severe Plaque Psoriasis 5 2025-05-08
A study to investigate improvement in pruritus of Lichen Simplex Chronicus with dupilumab injections compared with placebo in male and femal… Recruiting

2024-514737-37-00 Neurodermatitis 5 2025-03-06
Long-Term Safety and Efficacy evaluation of amlitelimab in participants of previous amlitelimab moderate to severe atopic dermatitis clinica… Recruiting

2023-506548-18-00 Dermatitis atopic 10 2022-11-10
A Study of Amivantamab in Addition to Standard of Care Agents Compared with Standard of Care in Participants With Recurrent/Metastatic Head … Recruiting

2025-521917-24-00 Treatment-Naïve Recurrent/Metastatic Head and Neck Squa 5 2026-01-21
A Study to compare RLY-2608 + Fulvestrant with Capivasertib + Fulvestrant in people with PIK3CA-mutated, hormone-receptor positive, HER2-neg… Recruiting

2025-523083-21-00 PIK3CA-mutant Hormone Receptor Positive, Human Epiderma 5 2025-12-08
A Phase 3 study of NBTXR3 with or without cetuximab in LA-HNSCC Recruiting

2024-520386-31-00 Locally Advanced Head & Neck Squamous Cell Carcinoma 5 2025-09-22
A study to understand if sotagliflozin improves symptoms and is safe in people with hypertrophic cardiomyopathy Recruiting

2024-513869-39-00 Obstructive Cardiomyopathy, Hypertrophic 5 2025-06-27
A trial to learn how well saruparib with camizestrant works and how safe it is in adults with advanced breast cancer that is hormone recepto… Recruiting

2023-504180-16-00 Advanced Breast Cancer 5 2025-04-07
Elacestrant versus Standard Endocrine Therapy in Women and Men with Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast C… Recruiting

2024-515445-42-00 Node-positive, Estrogen Receptor-positive, HER2-negativ 5 2025-03-24
A phase 3 study to evaluate petosemtamab vs. investigator's choice in previously treated metastatic / recurrent head and neck cancer. Recruiting

2023-510322-32-00 patients with incurable, metastatic/recurrent head and 5 2025-01-27
A phase 3 study to evaluate petosemtamab plus pembrolizumab vs pembrolizumab in first-line treatment of head and neck cancer Recruiting

2023-510323-30-00 First-line treatment of recurrent or metastatic PD-L1+ 5 2025-01-24
Evaluating how well and how safely Alisertib works with hormone therapy in treating patients with breast cancer that has come back or spread… Recruiting

2024-511497-79-00 Hormone receptor positive (HR+), human epidermal growth 4 2024-12-30
A phase 3 trial comparing a therapeutic cancer vaccine OSE2101 to chemotherapy docetaxel in patients with metastatic Non-Small Cell Lung Can… Recruiting

2023-509340-10-00 Patients with HLA-A2 positive phenotype and metastatic 5 2024-10-29
A Phase 3 study of Dostarlimab as Sequential Therapy after Chemoradiation compared to placebo in adult participants with Locally Advanced Un… Recruiting

2023-508613-17-00 Neoplasms, Head and Neck 5 2024-05-29
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) Recruiting

2023-504031-41-00 ER+/HER2- Early Breast Cancer 5 2024-03-25
A Long-Term Extension Study to Learn More About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adul… Recruiting

2023-504863-17-00 1. Lupus Erythematosus, Cutaneous, Subacute 2. Chronic 5 2024-02-21
Hidradenitis Suppurativa: Evaluation of Upadacitinib in Adult and Adolescent Subjects Recruiting

2023-503661-28-00 Hidradenitis Suppurativa 5 2023-10-26